[en] There is a growing interest for vitamin D in the medical and scientific community as well as in the public medias as illustrated by a huge number of publications. Most experts claim that vitamin D deficiency/insufficiency is widespread with potential important public health consequences. It may seem surprising for many persons that a deficiency in a vitamin may be so frequent in countries where food is so diversified and easily available. In fact, vitamin D is not a vitamin stricto sensu as it is mainly synthesized in the skin under the action of UVB rays, while its food sources are scarce. Furthermore, UVB rays are absent during a marked part of the year at latitudes greater than 35-40°, while pollution and cloud cover reduce the number of UVB reaching the earth, and many factors such as age, skin pigmentation, covering clothes, sun creams reduce the capacity of the skin to synthesize vitamin D3. Vitamin D must be hydroxylated to form 1,25dihydroxyvitamin D (1,25OH2D), the active metabolite. As 1,25OH2D is released into the bloodstream and binds to a receptor present in several distant tissues, it may be considered as a hormone, vitamin D being thus a pre-prohormone. In the present article, we review briefly the metabolism and various effects of vitamin D as well as the vitamin D assays and vitamin D treatments. We define vitamin D deficiency/insufficiency considering
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Souberbielle, Jean-Claude
CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Language :
English
Title :
Supplementation, optimal status, and analytical determination of vitamin D: Where are we standing in 2012?
Holick, M.F.; Chen, T.C.; Lu, Z.; Sauter, E. J. Vitamin and skin physiology: a delightful story. Bone Miner. Res., 2007, 2(suppl 2): V28-V33.
Schlingmann, K.P.; Kaufmann, M.; Weber, S.; Irwin, A.; Goos, C.; John, U.; Misselwitz, J.; Klaus, G.; Kuwertz-Bröking, E.; Fehrenbach, H.; Wingen, A.; Güran, T.; Hoenderop, J.; Bindels, R.; Prosser, D.; Jones, G.; Konrad, M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med., 2011, 365, 410-421.
Holick, M. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest., 2006, 116, 2062-2072.
Bischoff-Ferrari, H.; Willett, W.; Wong, J.; Stuck, A.; Staehelin, H.; Orav, J.; Thoma, A.; Kiel, D.; Henschkowski, J. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Arch. Int. Med., 2009, 169, 551-561.
Adami, S.; Giannini, S.; Bianchi, G.; Sinigalia, L. Di.; Munno, O.; Fiore, C.E.; Minisola, S.; Rossini, M. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos. Int., 2009, 20, 239-244.
Carmel, E.S.; Shieh, A.; Bang, H.; Bockman, R.S. The 25(OH)D level needed to maintain a favourable bisphosphonate response is >33 ng/mL. Osteoporos. Int., 2012, Jan 12 [Epub ahead of print].
Bischoff-Ferrari, H.; Dawson-Hughes, B.; Staehelin, H.B.; Orav, J.; Stuck, A.; Theiler, R.; Wong, J.; Egli, A.; Kiel, D.; Henschkowski, J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ, 2009, 339, b3692.
Hewison, M. Antibacterial effects of vitamin D. Nat. Rev. Endocrinol., 2011, 7, 337-345.
Boonstra, A.; Barrat, F.; Crain, C.; Heath, V.; Savelkoul, H.; O'Garra, A. 1,25-dihydroxyvitamin D3 has a direct effect on naïve CD4+T cells to enhance the development of Th2 cells. J. Immunol., 2001, 167, 4974-4980.
Pilz, S.; Tomaschitz, A.; Ritz, E. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol., 2009, 6, 621-630.
Ma, Y.; Zhang, P.; Wang, F.; Yang, J.; Liu, Z.; Qin, H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J. Clin. Oncol., 2011, 29, 3775-3782.
Bodnar, L.; Catov, J.; Simhan, H.; Holick, M.; Powers, R.; Roberts, J. Maternal vitamin D deficiency increases the risk of preeclampsia. J. Clin. Endocrinol. Metab., 2007, 92, 3517-3522.
Zhang, C.; Qiu, C.; Hu, F.; David, R.; van Dam, R.; Bralley, A.; Williams, M. Maternal plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus. PloS ONE, 2008, 3, e3753.
Brannon, P.; Picciano, M.F. Vitamin D in pregnancy and lactation in humans. Annu. Rev. Nutr., 2011, 31, 89-115.
Hollis, B.W.; Johnson, D.; Hulsey, T.C.; Ebeling, M.; Wagner, C. Vitamin D supplementation during pregnancy: double blind randomized clinical trial of safety and effectiveness. J. Bone Miner. Res., 2011, 26, 2341-2357
Holick, M.; Binkley, N.; Bischoff-Ferrari, H.; Gordon, C.; Hanley, D.; Heaney, R.; Murad, H.; Weaver, C. Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011, 96, 1911-1930.
Ross, C.; Manson, J.E.; Abrams, S.; Aloia, J.; Brannon, P.; Clinton, S.; Durazo-Arvizu, R.; Gallagher, J.C.; Gallo, R.; Jone, G.; Kovacs, C.; Mayne, S.; Rosen, C.; Shapes, S. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab., 2011; 96, 53-58.
Munger, K.; Levin, L.; Hollis, B.; Howard, N.; Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 2006, 296, 2832-2838.
Giovanucci, E. Epidemiological evidence for vitamin D and colorectal cancer. J. Bone Miner. Res., 2007, 22, V81-V85.
Engel, P.; Fagherazzi, G.; Boutten, A.; Dupré, T.; Mesrine, S.; Boutron-Ruault, M.C.; Clavel-Chapelon, F. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 2341-2350.
Leu, M.; Giovannucci, E. Vitamin D: epidemiology of cardiovascular risks and events. Best Pract. Res. Cl. En., 2011, 25, 633-646.
Adams, J.; Hewison, M. Update in vitamin D. J. Clin. Endocrinol. Metab., 2010, 95, 471-478.
Norman, A. Vitamin D nutrition is at a crossroads. Public Health Nutrition, 2011, 14, 750-751.
Dawson-Hughes, B.; Mithal, A.; Bonjour, J.P.; Boonen, S.; Burckardt, P.; Fuleihan, G.E.H.; Josse, R.G.; Lips, P.; Morales-Torres, J.; Yoshimura, N. IOF position statements: vitamin D recommendations for older adults. Osteoporos. Int., 2010, 21, 1151-1154.
Perez-Lopez, F.; Brincat, M.; Erel, T.; Erel, T.; Tremollieres, F.; Gambacciani, M.; Lambrinoudaki, I.; Moen, M.; Schenck-Gustafsson, K.; Vujovic, S.; Rozenberg, S.; Rees, M. EMAS position statement: vitamin D and postmenopausal health. Maturitas, 2012, 71, 194-198.
Vieth, R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J. Steroid Biochem. Mol. Biol., 2004, 89, 575-579.
Bischoff-Ferrari, H.; Giovanucci, E.; Willett, W.; Dietrich, T.; Dawson-Hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple outcomes. Am. J. Clin. Nutr., 2006, 84, 18-28.
Dawson-Hughes, B.; Heaney, R.; Holick, M.; Lips, P.; Meunier, P.; Vieth, R. Estimates of optimal vitamin D status. Osteoporos. Int., 2005, 16, 713-716.
Hanley, D.; Cranney, A.; Jones, G.; Whiting, S.; Leslie, W.; Cole, D.; Atkinson, S.; Josse, R.; Feldman, S.; Kline, G.; Rosen, C. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ, 2010, 182, E610-E618.
Souberbielle, J.C.; Body, J.J.; Lappe, J.; Plebani, M.; Schoenfeld, Y.; Wang, T.; Bischoff-Ferrari, H.; Cavalier, H.; Ebeling, P.; Fardellone, P.; Gandini, S.; Gruson, D.; Guerin, A.; Heickendorff, L.; Hollis, B.; Ish-Shalom, S.; Jean, G.; von Landenberg, P.; Largura, A.; Olsson, T.; Pierrot-Deseilligny, C.; Pilz, S.; Tincani, A.; Valcour, A.; Zittermann, A. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmunity Reviews, 2010, 9, 709-715.
Priemel, M.; von Domarus, C.; Klatte, T.O.; Kessler, S.; Schlie, J.; Meier, S.; Proksch, N.; Pastor, F.; Netter, C.; Streichert, T.; Püschel, K.; Amling, M. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res., 2010, 25, 305-312.
Okazaki, R.; Sugimoto, T.; Kaji, H.; Fujii, Y.; Shiraki, M.; Inoue, D.; Endo, I.; Okano, T.; Hirota, T.; Kurahashi, I.; Matsumoto, T. Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D3 supplementation load in Japanese patients. J. Bone Miner. Metab., 2011, 29, 103-110.
Chapuy, M.C.; Preziosi, P.; Maamer, M.; Arnaud, S.; Galan, P.; Hercberg, S.; Meunier, P.J. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int., 1997, 7, 439-443.
Heaney, R.; Dowell, M.; Hale, C.; Bendich, A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr., 2003; 22: 142-146.
Mithal, A.; Wahl, D.A.; Bonjour, J.P.; Burckardt, P.; Dawson-Hughes, B.; Eisman, J.; Fuleihan, G.E.H.; Josse, R.; Lips, P.; Morales-Torres, J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int., 2009, 11,1807-1820.
Hathcock, J.; Shao, A.; Vieth, R.; Heaney, R. Risk assessment for vitamin D. Am. J. Clin. Nutr., 2007, 85: 6-18.
Tuohimaa, P.; Tenkanen, L.; Ahonen, M.; Lumme, S.; Jellum, E.; Hallmans, G.; Stattin, P.; Harvei, S.; Hakulinen, T.; Luostarinen, T.; Dillner, J.; Lehtinen, M.; Hakama, M. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer, 2004,108,104-108.
Stolzenberg-Solomon, R.Z.; Jacobs, E.J.; Arslan, A.A.; Qi, D.; Patel, A.V.; Helzlsouer, K.J.; Weinstein, S.J.; McCullough, M.L.; Purdue, M.P.; Shu, X.; Snyder, K.; Virtamo, J.; Wilkins, L.; Yu, K.; Zelenius-Jacquotte, A.; Zheng, W.; Albanes, D.; Cai, Q.; Harvey, C.; Hayes, R.; Clipp, S.; Horst, R.L.; Irish, L.; Koenig, K., Le Marchand, L.; Kolonel, L.N. Circulating 25-hydroxyviatmin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am. J. Epidemiol., 2010, 172, 81-93.
Luxwolda, M.; Kuiperst, R.; Kema, I.; Dijck-Brouwer, J.; Muskiet, F. Traditionnally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/L. British Journal of Nutrition, 2012, Jan 23, 1-5 [Epub ahead of print]
Hollis, B.W. The determination of circulating 25-hydroxyvitamin D: no easy task. J. Clin. Endocrinol. Metab., 2004, 89, 3149-3151.
Lensmeyer, G.; Poquette, M.; Wiebe, D.; Binkley, N. The C3-epimer of 25-hydroxyvitamin D3 is present in adult serum. J. Clin. Endocrinol. Metab., 2012, 97, 163-168.
Elder, P.; Lewis, J.; King, R.; Florkowski, C. An anomalous result from gel tubes for vitamin D. Clinica Chimica Acta, 2009, 410, 95.
Carter, G.; Jones, J.C.; Berry, J.L. The anomalous behaviour of exogenous 25-hydroxyvitamin D in competitive binding assays. J. Steroid Biochem. Mol. Biol., 2007, 103, 480-482.
Cavalier, E.; Wallace, M.; Knox, S.; Mistretta, V.; Cormier, C.; Souberbielle, J.C. Serum vitamin D measurement may not reflect what you give to your patients. J. Bone Miner. Res., 2008, 23, 1864-1865.
Binkley, N.; Drezner, M.; Hollis, B.W. Laboratory reporting of 25-hydroxyvitamin D results: potential for clinical misinterpretation. Clin. Chem., 2006, 52, 2124-2125.
Hollis, B.W. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin. Chem., 2000, 46, 1657-1661.
Stepman, H.; Vanderroost, A.; Van Uytfanghe, K.; Thienpont, L. Candidate reference measurement procedures for serum 25OHD3 and 25OHD2 by using isotope dilution liquid chromatographytandem mass spectrometry. Clin. Chem., 2011, 57, 441-448.
Heijboer, A.; Blankenstein, M.; Kema, I.; Buijs, M. Accuracy of 6 routine 25-hydroxyvitamin D assays; influence of vitamin D binding protein concentration. Clin. Chem., 2012, 58 in press.
Farrell, C.J.; Martin, S.; McWhinney, B.; Straub, I.; Williams, P.; Hermann, M. State-of-the-art vitamin assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin. Chem., 2012, 53 in press.
Taieb, J.; Mathian, B.; Millot, F.; Patricot, M.C.; Mathieu, E.; Queyrel, N.; Lacroix, I.; Somma-Delpero, C.; Boudou, P. Testosterone measured by 10 immunoassays and by isotopedilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin. Chem., 2003, 49, 1381-1395.
Boudou, P.; Taieb, J.; Mathian, B.; Badonnel, Y.; Lacroix, I.; Mathieu, E.; Millot, F.; Queyrel, N.; Somma-Delpero, C.; Patricot, M.C. Comparison of progesterone concentration determination by 12 non-isotopic immunoassays and gas chromatography/mass spectrometry in 99 human serum samples. J. Steroid Biochem. Mol. Biol., 2001, 78, 97-104.
Barake, M.; Daher, R.; Salti I, Cortas N, Al-Saar L, Habib R, El-Hajj-Fuleihan G. 25-hydroxyvitamin D assay variations and impact on clinical, decision making. J Clin Endocrinol metab, 2012; 97: 835-843.
Binkley, N.; Krueger, D.; Cowgill, C.S.; Plum, L.; Lake, E.; Hansen, K.E.; DeLuca, H.; Drezner, M. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J. Clin. Endocrinol. Metab., 2004, 89, 3152-3157.
Hyppönen, E.; Turner, S.; Cumberland, P.; Power, C.; Gibb, I. Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J. Clin. Endocrinol. Metab., 2007, 92, 4615-4622.
Cavalier, E.; Rozet, E.; Gadisseur, R.; Carlisi, A.; Monge, M.; Chapelle, J.P.; Hubert, P.; Souberbielle, J.C.; Delanaye, P. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cutoffs. Osteoporos. Int., 2010, 21, 1047-1051.
Davidson, Z.; Walker, K.; Truby, H. Do glucocorticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J. Clin. Endocrinol. Metab., 2012, 97, 738-744.
KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int., 2009, 79, S1-S130.
Kandula, P.; Dobre, M.; Schold, J.D.; Schreiber, M.; Mehrotra, R.; Navaneethan, S. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol., 2011, 6, 50-62.
Jean, G.; Souberbielle, J.C.; Chazot, C. Strategy for vitamin D supplementation. Monthly cholecalciferol administration in hemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol. Dial. Transplant., 2009, 24, 3799-3805.
Matias, P.J.; Jorge, C.; Ferreira, C.; Borges, C.; Aires, I.; Amaral, T.; Gil, C.; Cortez, J.; Ferreira, A. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimensions parameters. Clin. J. Am. Soc. Nephrol., 2010, 5, 905-911.
Courbebaisse, M.; Thervet, E.; Souberbielle, J.C.; Zuber, J.; Eladari, D.; Martinez, F.; Mamzer-Bruneel, M.F.; Urena, P.; Legendre, C.; Friedlander, G.; Prié, D. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int., 2009, 75, 646-651.
Pilz, S.; Iodice, S.; Zittermann, A.; Grant, W.; Gandini, S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am. J. Kidney Dis., 2011, 58, 374-382.
de Boer, I.H.; Katz, R.; Chonchol, M.; Sarnak, M.; Shlipak, M.; Siskovick, D.; Kestenbaum, B. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin. J. Am. Soc. Nephrol., 2011, 6, 2141-2149.
Kim, M.J.; Frankel, A.; Donaldson, M.; Darch, S.; Pusey, C.; Hill, P.; Mayr, M.; Tam, F. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin -aldosterone system inhibition. Kidney Int., 2011, 80, 851-860.
Grey, A.; Lucas, J.; Horne, A.; Gamble, G.; Davidson, J.; Reid, I. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab., 2005, 90, 2122-2126.
Souberbielle, J.C.; Maury, E.; Friedlander, G.; Cormier, C. Vitamin D and primary hyperparathyroidism (PHPT). J. Steroid. Biochem. Mol. Biol., 2010, 121, 199-203.
Eastell, R.; Arnold, A.; Brandi, M.L.; Brown, E.; D'Amour, P.; Hanley, D.; Rao, S.; Rubin, M.; Goltzman, D.; Silverberg, S.; Marx, S.; Peacock, M.; Mosekilde, L.; Bouillon, R.; Lewiecki, E. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab., 2009, 94, 340-350.
Lowe, H.; McMahon, D.J.; Rubin, M.; Bilezikian, J.; Silverberg, S. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab., 2007, 92, 3001-3005.
Heaney, R.P. Vitamin D in health and disease. Clin. J. Am. Soc. Nephrol., 2008, 3, 1535-1541.
Cashman, K.; Fitzgerald, A.; Kiely, M; Seamans, K. A systematic review and meta-regression analysis of the vitamin D intake-serum 25-hydroxyvitamin D relationship to inform European recommendations. Br. J. Nutr., 2011, 106, 1617-1627.
Gallagher, J.C.; Sai, A.; Templin III, T.; Smith, L. Dose response to vitamin D supplementation in postmenopausal women. A randomized trial. Ann. Intern. Med., 2012, 156, 425-437.
Toss, G.; Magnusson, P. Is a daily supplementation with 40 microgram vitamin D3 sufficient? A randomikzed trial. Eur. J. Nutr., 2011, [Epub ahead of print].
Diamond, T.; Wong, Y.K.; Golombick, T. Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency. Osteoporos. Int., 2011, Epub ahead of print
van Groningen, L.; Opdenoordt, S.; van Sorge, A.; Telting, D.; Giesen, A.; de Boer, H. Choecalciferol loading dose guideline for vitamin D deficient adults. Eur. J. Endocrinol., 2010, 162, 805-11.
Holick, M.F. Vitamin D deficiency. N. Engl. J. Med., 2007, 357, 266-81.
Ish-Shalom, S.; Segal, E.; Salganik, T.; Raz, B.; Bromberg, I.; Vieth, R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J. Clin. Endocrinol. Metab., 2008, 93, 3430-3435.
Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.; Kotowicz, M.; Young, D.; Nicholson, G. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. J.A.M.A., 2010, 303, 1815-1822.
Armas, L.A.G.; Hollis, B.W.; Heaney, R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab., 2004, 89, 5387-5391.
Romagnoli, E.; Mascia, M.L.; Cipriani, C.; Fassino, V.; Mazzei, F.; D'Erasmo, E.; Carnevale, V.; Scillitani, A.; Minisola, S. Short and long term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamine D3) in the elderly. J. Clin. Endocrinol. Metab., 2008, 93, 3015-3020.
Holick, M.; Biancuzzo, R.M.; Chen, T.C.; Klein, E.; Young, A.; Bibuld, D.; Reitz, R.; Salameh, W.; Ameri, A.; Tannenbaum, A. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrino.l Metab., 2008, 93, 677-681.
Heaney, R.; Recker, R.; Grote, J.; Horst, R.; Armas, L. Vitamin D3 is more potent than vitamin D2 in humans. J. Clin. Endocrinol. Metab., 2011, 96, E447-E452.